NPI: 1659674190 · BIRMINGHAM, AL 35207 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 12/06/2010
Authorized official WINSTEL, JOHN controls 20+ related entities in our dataset. Read more
| Authorized Official | WINSTEL, JOHN (CHIEF ACCOUNTING OFFICER, TREASURER) |
| NPI Enumeration Date | 12/06/2010 |
Other providers sharing the same authorized official: WINSTEL, JOHN
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 8,044 | $223K |
| 2019 | 9,333 | $204K |
| 2020 | 9,988 | $196K |
| 2021 | 4,939 | $90K |
| 2022 | 1,755 | $44K |
| 2023 | 281 | $8K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 12,532 | 999 | $536K |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 11,836 | 632 | $203K |
| J1756 | Injection, iron sucrose, 1 mg | 2,496 | 554 | $16K |
| J1270 | Injection, doxercalciferol, 1 mcg | 4,690 | 406 | $3K |
| 83970 | 178 | 157 | $2K | |
| A4657 | Syringe, with or without needle, each | 564 | 492 | $1K |
| 83550 | 204 | 157 | $706.20 | |
| 82728 | 243 | 186 | $650.18 | |
| 82108 | 83 | 76 | $562.05 | |
| 85041 | 435 | 353 | $439.27 | |
| 83540 | 188 | 145 | $409.69 | |
| 85048 | 435 | 353 | $408.75 | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 456 | 263 | $0.00 |